Serum sonic hedgehog (SHH) and interleukin-(IL-6) as dual prognostic biomarkers in progressive metastatic breast cancer

Serum from one hundred and ten breast cancer patients and thirty healthy female volunteers, were prospectively collected and evaluated for serum levels of Shh and IL-6 using human Shh and IL-6 specific enzyme-linked immunoassays. All patients were regularly monitored for event free survival (EFS) an...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports Vol. 7; no. 1; pp. 1796 - 12
Main Authors: Noman, A. S., Uddin, M., Chowdhury, A. A., Nayeem, M. J., Raihan, Z., Rashid, M. I., Azad, A. K., Rahman, M. L., Barua, D., Sultana, A., Shirin, A., Ferdous, J., Parag, R. R., Rahman, S. M., Mahmud, M. R., Jerin, C. S., Jahan, N., Siddiqua, A., Ara, T., Sabur, E. B., Alam, S. S., Baidya, S., Akther, S., Rahman, M. Z., Banu, T., Murugan, A. K., Sabri, S., Islam, S. M. S., Karakas, B., Aboussekhra, A., Yeger, H., Farhat, W. A., Islam, S. S.
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 11.05.2017
Nature Publishing Group
Nature Portfolio
Subjects:
13
13/21
13/31
14
14/1
14/105
14/19
38
38/91
631/67/1347
631/67/1857
Biomarkers
Biomarkers, Tumor
Bone Neoplasms - secondary
Breast cancer
Breast Neoplasms - blood
Breast Neoplasms - diagnosis
Breast Neoplasms - mortality
Case-Control Studies
Disease Progression
Female
Hedgehog protein
Hedgehog Proteins - blood
Humanities and Social Sciences
Humans
Immunoassays
Interleukin 6
Interleukin-6 - blood
Lymph nodes
Metastases
Metastasis
multidisciplinary
Neoplasm Metastasis
Neoplasm Staging
Prognosis
ROC Curve
Science
Science (multidisciplinary)
Serum levels
Statistical analysis
Survival
Whole Body Imaging
ISSN:2045-2322, 2045-2322
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Serum from one hundred and ten breast cancer patients and thirty healthy female volunteers, were prospectively collected and evaluated for serum levels of Shh and IL-6 using human Shh and IL-6 specific enzyme-linked immunoassays. All patients were regularly monitored for event free survival (EFS) and overall survival (OS). Overall outcome analysis was based on serum Shh and IL-6 levels. In patients with progressive metastatic BC, both serum Shh and IL-6 concentrations were elevated in 44% (29 of 65) and 63% (41 of 65) of patients, respectively, at a statistically significant level [Shh (p = 0.0001) and IL-6 (p = 0.0001)] compared to the low levels in healthy volunteers. Serum levels tended to increase with metastatic progression and lymph node positivity. High serum Shh and IL-6 levels were associated with poor EFS and OS opposite to the negative or lower levels in serum Shh and IL-6. The elevated levels of both serum Shh and IL-6 were mainly observed in BC patients who had a significantly higher risk of early recurrence and bone metastasis, and associated with a worse survival for patients with progressive metastatic BC. Further studies are warranted for validating these biomarkers as prognostic tools in a larger patient cohort and in a longer follow-up study.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-017-01268-4